PUXANO is a discovery partner for pharma and biotech teams, specialised in structure-guided antigen design, membrane protein research and cryo-EM protein structure determination.
At PUXANO, collaborating with us means gaining access to a unique platform and a dedicated team fully committed to advancing your programs. We offer specialized discovery programs next to gene-to-structure workflow, that are build upon our proprietary de novo generated protein scaffolds and cryoEM grid portfolio. Specific case studies include: generating soluble analogues of membrane proteins, integrating multiple separate epitopes into a single scaffold (multi-epitope scaffolds), stabilizing multimeric protein assemblies via de novo scaffolds or transforming monomeric proteins into larger multimeric assemblies. The development of these novel strategies has led to a growing library of antigens of different bacterial and viral pathogens.
For vaccine and antibody development
We transform your specific protein target into an antigen for vaccine or antibody development. Via our protein design technologies, we maximize characteristics such as yield, stability and immunogenicity.
For high-throughput drug screening
We facilitate the expression, biophysical screening and structural characterization of your target membrane protein by different protein design strategies leveraging on our de novo designed biotechnology tools.
For proteins not accessible via standard cryoEM sample preparation procedures
We screen your protein sample across several grid types to resolve problems such as low yield, protein complex disassembly or preferred particle orientation. We have also developed specific protocols to determine structures of proteins isolated from a native context (primary cells or patient-derived materials).
In all these programs, we combine the strengths of our platform technologies with state-of-the-art labs and expert personnel. Our facilities are equipped to support insect, mammalian, and bacterial cell growth, protein quality analysis (including yield, purity, monodispersity, and stability), binding assays for small and large molecules, functional assays, and cryoEM-based protein structure determination. Together, this enables us to unlock access to your most challenging targets. We understand that every project is unique, which is why we offer flexible partnering models designed to align with your objectives. Our approach provides the right level of access and support to drive your goals forward.
Work with PUXANO’s expert team to advance your program using our proprietary discovery platform, available in both exclusive and non-exclusive formats. Our funded discovery model is ideal if you want our scientists to drive antigen design for vaccine or antibody development or to screen small molecules in silico and experimentally against challenging membrane protein targets or protein structures derived from patient-derived materials. Within 6–12 months of project initiation, we deliver high-quality antigens or protein structures from native resources, detailed data packages, and actionable insights to keep your pipeline moving forward with confidence.
Depending on the project and client needs, we can operate as a contract research organization (CRO) or as a discovery partner, with flexible fee structures that incorporate upfront payments, success fees, milestones, or royalties.
Our platform is continuously evolving, and we actively apply it to real-world proteins, including the most challenging targets. This has lead to a library of IP-protected proteins that can be accessed through a licensing model, allowing you to immediately use them for internal vaccine or antibody development or to leverage them for small molecule drug screening. This approach ensures you can accelerate your pipeline without delays, quickly securing your competitive position in drug development.
Stay updated on the latest in protein design, AI-driven engineering, and groundbreaking research. Subscribe now to get exclusive insights and updates.
